188 related articles for article (PubMed ID: 20666740)
1. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
Hasselbalch B; Eriksen JG; Broholm H; Christensen IJ; Grunnet K; Horsman MR; Poulsen HS; Stockhausen MT; Lassen U
APMIS; 2010 Aug; 118(8):585-94. PubMed ID: 20666740
[TBL] [Abstract][Full Text] [Related]
2. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Sathornsumetee S; Cao Y; Marcello JE; Herndon JE; McLendon RE; Desjardins A; Friedman HS; Dewhirst MW; Vredenburgh JJ; Rich JN
J Clin Oncol; 2008 Jan; 26(2):271-8. PubMed ID: 18182667
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
[TBL] [Abstract][Full Text] [Related]
4. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Jakobsen JN; Hasselbalch B; Stockhausen MT; Lassen U; Poulsen HS
Expert Opin Pharmacother; 2011 Apr; 12(5):825-33. PubMed ID: 21385110
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
[TBL] [Abstract][Full Text] [Related]
10. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
[TBL] [Abstract][Full Text] [Related]
11. Development and clinical indications of cetuximab.
Labianca R; La Verde N; Garassino MC
Int J Biol Markers; 2007; 22(1 Suppl 4):S40-6. PubMed ID: 17520580
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
14. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
16. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Ringelstein A; Turowski B; Gizewski ER; Schroeteler J; Rapp M; Saleh A; Lanzman RS; Mathys C; Sabel M; Mödder U
Rofo; 2010 Oct; 182(10):868-72. PubMed ID: 20740393
[TBL] [Abstract][Full Text] [Related]
20. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
